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LETTERS TO THE EDITOR 
Transesophageal Echocardiography Versus 
Oral Anticoagulation Before Electrical 
Cardioversion of Atrial Fibrillation: 
What About Atrial Clot Size? 
In their article (1) Manning et al. conclude that transesophageal 
echocardiography offers the security of performing electrical cardio- 
version in atrial fibrillation without preventive oral anticoagulation 
when no thrombus is found in the atria. Their great expertise in 
transesophageal chocardiography certainly contributes to their excel- 
lent results, with no embolic events in their series. 
The authors have to be congratulated for their precision with 
regard to the size of the thrombus that they found in the atria, from 2 
to 20 mm in maximal length. However, this size is quite small, and one 
can easily guess than an atrial clot of 2 mm may be difficult to detect 
and may be missed. What about a smaller clot, or several of them, 
1.5 mm long, for instance? 
Strangely enough, the size of the clots able to produce a cerebral 
attack is never mentioned in reports of cerebral emboli. In fact, the 
only information that I was able to find on this point was an 
advertisement published in most U.S. journals of cardiology from a 
drug company selling a widely used oral anticoagulant in the United 
States. This advertisement shows at the top of a full white page a very 
small clot of 1 or 2 ram, said to be shown in its actual size and accused 
of being able to produce disastrous cerebral alterations. Unfortunately, 
the reference given to support his affirmation was misleading in that 
it did not mention any size of any clot. 
However, even without objective demonstration f this fact, it is 
easy to suppose that a very small clot, under the critical size that can 
be detected by transesophageal chocardiography, for instance, 1 or 
1.5 ram, reaching acerebral artery of critical importance, although only 
1 or 2 mm in diameter, such as the terminal branch of the sylvian 
artery, may have disastrous neurological consequences. 
It therefore appears to me that there is no reason to risk relying on 
transesophageal echocardiography instead of applying the classical 
treatment with 3 or 4 weeks of preventive oral anticoagulants before 
performing an electrical cardioversion. This treatment, for so short a 
time, is simple to apply, not costly, and much more comfortable for the 
patient han enduring the unpleasant passage of the large tubing of the 
transesophageal chocardiography in the throat if there is no specific 
indication for this procedure. The risk of hemorrhagic complication 
with such a short period of anticoagulation is practically zero. 
In addition, a report such as that by Manning et al. may push less 
experienced echocardiographers to rely on the less accurate results of 
transesophageal chocardiography, resulting in more embolic ompli- 
cations, whereas oral anticoagulation does not require any sophisti- 
cated expertise. 
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Reply 
We agree with Letac that migration of very small thrombi may 
potentially lead to significant morbidity and that data are lacking with 
regard to the clinical implications of these thrombi. Our hypothesis was 
that transesophageal echocardiography will allow identification of 
clinically relevant atrial thrombi. Because of our concern regarding 
visualization of very small thrombi, we have always emphasized the 
importance of therapeutic anticoagulation with heparin (or warfarin) 
at the time of transesophageal chocardiography, extending through 
cardioversion and for 1 month after cardioversion. 
We believe the patient admitted to the hospital with atrial fibrilla- 
tion does benefit from a transesophageal echocardiography guided 
strategy for early cardioversion. Such a strategy markedly abbreviates 
the total duration of oral anticoagulation, leads to a more prompt 
return of atrial mechanical function (1) and is cost-effective (2,3). These 
benefits are most apparent for symptomatic patients with a relatively brief 
(<4 week) duration of atrial fibrillation (1). Our large prospective and 
nearly consecutive study validates the safety of the transesophageal 
echocardiography approach as being equivalent to conventional therapy. 
Using a similar transesophagea[ chocardiography/anticoagulation strat- 
egy, comparable data have been published by others (4,5). We do not 
claim that the transesophageal chocardiography guided strategy issafer 
than conventional therapy. This hypothesis i  being tested by the ongoing 
multicenter Assessment of Cardioversion Using Yransesophageal Echo- 
cardiography (ACUTE) trial (5). The benefit for outpatients and those 
who have been in atrial fibrillation for several months is also less clear and 
remains to be defined by the ACUTE trial. The clinical results of less 
experienced echocardiographers is unknown but should be similar, as- 
suming that they perform transesophageal echocardiography studies 
according to our recommendations and that they use biplane or multi- 
plane transesophageal echocardiography robes. Situations in which there 
is failure to adequately visualize the atrium/appendage, or in which a clot 
is suspected but cannot be definitively diagnosed, should be treated with 
conventional therapy of 1 month of warfarin before cardioversion. 
We strongly disagree that conventional therapy of 3 to 4 weeks of 
warfarin before cardioversion does not convey "any risk." Although no 
randomized trial results have been reported, and data from only one 
prospective trial are available (5), other reports document a risk of 
thromboembolism of up to 1.6% among patients using conventional 
strategy (6,7). Similarly, we disagree that the risk of short-term 
anticoagulant therapy is practically "zero" and that "oral anticoagula- 
tion does not require any sophisticated xpertise." Anticoagulation is 
prescribed for 1 month after cardioversion during return of atrial 
mechanical function and for prophylaxis should the patient revert o 
atrial fibrillation. In a study of patients with atrial fibrillation receiving 
warfarin specifically in preparation for cardioversion, o patient who 
received warfarin for <1 month experienced a hemorrhagic complica- 
tion compared with 2% of those who received warfarin for longer 
periods (8). Similar hemorrhagic data were reported in the prospective 
ACUTE pilot study (5). Finally, maintenance of therapeutic prothrom- 
bin time for 3 to 4 weeks before cardioversion can be difficult, often 
resulting in further delay in cardioversion (5). Use of a transesopha- 
geal echocardiography guided strategy eliminates this delay in cardio- 
01996 by the American College of Cardiolo~' 0735-1097/96/$15.00 
0735- 1097(95 )00418-7 
